China’s CAR-T Programmes, Open to International Patients
StarWay Bio is our cell and gene therapy partner in China, connecting patients from abroad to the hospitals licensed to deliver the country’s approved CAR-T therapies — for lymphoma, leukaemia, myeloma and, since June 2026, the world’s first CAR-T approved for a solid tumour. Your case is managed by MedVoyage Global throughout.
Not a Product. The Whole Field.
Most people who ask about CAR-T in China have already been through several rounds of treatment at home and have been told the options are thinning. That is a bad moment to be sold something. It is a good moment to have someone read the data properly and tell you what is genuinely available.
Access to the Whole Approved Field
StarWay Bio works across the licensed CAR-T products rather than representing one manufacturer. That matters, because the right therapy is decided by your disease and your target — CD19, BCMA or Claudin18.2 — not by whose product someone happens to sell.
Designated Treatment Centres Only
CAR-T is delivered in China exclusively at hospitals licensed for each specific product. Their collaboration network covers essentially all of those designated centres, so the case can be routed to the centre that is actually authorised to treat you.
A Clinical Research Background
StarWay Bio is a contract commercial organisation for cell and gene therapy — protocol design, trial monitoring, biostatistics and regulatory work across CAR-T, TCR, AAV gene therapy and antibody-drug conjugates. They read the data for a living rather than reading a brochure.
Screened, Documented, Compliant
Partner institutions pass qualification review covering research capability, equipment and personnel credentials. Work runs to standard operating procedures under NMPA regulation, and patient records are handled under China’s data protection law.
Eligibility for CAR-T turns on details buried in the pathology, the flow cytometry and the record of what has already been tried. Getting those documents in front of the right haematologist is the part we handle.
Your Own Immune System, Re-Armed
CAR-T is not a drug taken off a shelf. It is a treatment manufactured from your own cells, for you alone, in five stages spread over several weeks. Knowing what those stages are makes the rest of this page — the timelines, the costs, the risks — a great deal easier to read.
Your Cells Are Collected
T-cells — the immune system’s killers — are separated out of your blood in a procedure similar to giving plasma. Nothing is taken from a donor. The starting material is you.
They Are Re-Engineered
In the manufacturing facility, a gene is inserted that makes those T-cells display a chimeric antigen receptor — a lock built to fit one protein on the surface of your cancer cells, and to ignore everything else.
They Are Grown Into an Army
The modified cells are expanded outside the body until there are enough of them to matter, then tested for potency, sterility and identity before anything is released. This stage takes weeks, not days.
Your Marrow Is Prepared
A short course of lymphodepleting chemotherapy clears space so the engineered cells have room to expand once they are returned. It is preparation for the treatment, not the treatment itself.
They Go Back In
The cells are infused back into your bloodstream in a single dose. From there they multiply inside you, hunt the target protein and keep working — which is why one infusion can produce years of response.
The Same Science at a Quarter of the Price
China did not arrive at CAR-T late and cheap. It has more approved products than anywhere else, starts more trials than any other country, and in June 2026 became the first to license a CAR-T therapy for a solid tumour — something no other regulator has yet done.
Indicative band for commercial CAR-T, therapy only (USD)
60–70% less than the USIndicative band for commercial CAR-T, therapy only (USD)
Before hospital & support feesTwo-thirds of the world total
The established Western field
Satri-cel, approved June 2026 for gastric and gastro-oesophageal junction cancer
No licensed solid-tumour CAR-T at this scale
More trial starts than any other country since 2024
The largest body of long-term follow-up
Across published registrational studies
Similar outcomes at roughly four times the price
79.3% complete response
Comparable published results
Indicative band, therapy only
Before hospital and support fees
A range is not a quote. The figures above are indicative bands for the therapy itself, drawn from published pricing and from data supplied by our partner. Hospital admission, lymphodepletion, bridging treatment, management of complications, length of stay and travel are additional and depend entirely on your case. Response rates are reported across different products, indications and patient populations, and are not a prediction for any individual patient.
Six Approved Pathways
Each approved product targets one protein and is licensed for one set of circumstances. Almost all require that a defined number of previous treatments have already been tried and have stopped working — which is the honest way to read the word “refractory”.
Large B-Cell Lymphoma
The indication CAR-T was built for, and the one with the longest follow-up anywhere. China’s first approved product has real-world five-year survival data behind it rather than projections.
Follicular Lymphoma
An indolent lymphoma that tends to keep returning. Published Chinese results in this group report every patient alive at two years, with most showing no disease progression over that period.
B-Cell Acute Lymphoblastic Leukaemia
An aggressive leukaemia where remission has usually been tried and lost more than once. CAR-T is used here precisely because conventional chemotherapy has already been exhausted.
Paediatric & Young-Adult B-ALL
A licensed pathway specifically for children and young adults — the group where relapse after remission is most devastating and where a dedicated product, rather than an adult dose scaled down, genuinely matters.
Multiple Myeloma
A different target for a different disease. Reported response rates approach nine in ten patients, with the majority reaching complete response — in people whose myeloma has already outrun several treatments.
Gastric & Gastro-Oesophageal Cancer
Satri-cel — the world’s first CAR-T approved for a solid tumour, licensed in China in June 2026. Solid tumours had resisted this approach everywhere for a decade. This is the reason people are now looking at China specifically, and it is set out in full further down this page.
Satri-cel, for Advanced Stomach Cancer
For a decade CAR-T worked in blood cancers and failed in solid ones. Satri-cel (satricabtagene autoleucel) is the therapy that broke that pattern: approved by China’s National Medical Products Administration for Claudin18.2-positive, HER2-negative advanced gastric and gastro-oesophageal junction adenocarcinoma in patients who have already failed at least two lines of treatment.
It targets Claudin18.2, a protein that sits hidden inside healthy stomach lining but becomes exposed on the surface of cancer cells — which is what makes it possible to aim at the tumour without destroying the organ around it.
From CT041-ST-01, the randomised confirmatory study behind the approval. Figures compare satri-cel against the treatment the investigator would otherwise have chosen.
Objective response rate
Against 4% on the control arm, which received the investigator’s choice of apatinib, paclitaxel, docetaxel, irinotecan or nivolumab. Ten times the response, in patients whose cancer had already outrun at least two lines of treatment.
Disease control rate
Tumours shrank or stopped growing in four patients out of five, against 27% on the control arm. No patient in either group reached a complete response.
Median progression-free survival
Against 1.7 months on the control arm — a 70% reduction in the risk of progression or death (HR 0.299, 95% CI 0.195–0.457).
Median overall survival
Across all 108 patients who received satri-cel, against 3.98 months for those who did not. The randomised comparison, adjusted for crossover, showed a 53–63% reduction in the risk of death.
Who It Is For
The criteria the study used, and broadly what a treating centre will assess against. Meeting them on paper is the start of the conversation, not the end of it.
- Advanced gastric or gastro-oesophageal junction adenocarcinoma, confirmed on pathology
- Claudin18.2-positive on immunohistochemistry — 2+ or 3+ staining in at least 40% of tumour cells
- HER2-negative
- At least two previous lines of therapy already tried and failed
- At least one measurable lesion on imaging
- ECOG performance status 0 or 1 — up and about, and self-caring
- The study enrolled adults aged 18 to 75
Nothing Starts Until the Tumour Is Tested
Claudin18.2 is found by staining tumour tissue that has already been taken — usually the biopsy or resection specimen you or your hospital already hold. China’s CSCO gastric cancer guidelines raised that test to a Level I, Category 1B recommendation in 2025, up from Level II the year before. Roughly 60% of gastric cancer patients express the protein.
Where the threshold is drawn decides who qualifies. Satri-cel was studied at 2+ or 3+ staining in 40% of tumour cells or more — a wider door than the cut-offs used in Claudin18.2 antibody trials.
Share of gastric cancers testing positive at each threshold, across 536 patients in the CT041 studies and published antibody-trial cohorts.
How the Course Actually Runs
Four stages, in this order. The gap between the first and the last is measured in weeks, which is the single biggest thing to plan a trip around.
Apheresis
Your own T-cells are collected from your blood. This is the starting material — nothing comes from a donor.
Bridging Therapy
Treatment to hold the disease steady while the cells are manufactured. Gastric cancer does not wait politely, so this stage is part of the protocol rather than an afterthought.
Lymphodepletion
A short conditioning course that clears room for the engineered cells to expand once they are returned.
Infusion
A dose of 250 million CAR-positive T-cells. The protocol allows re-infusion up to three times if the treating team judges it appropriate.
What the Safety Data Says
The two side effects that define CAR-T are cytokine release syndrome and neurotoxicity. In this study both were unusually contained — but read the fourth figure as carefully as the first three.
Severe cytokine release syndrome
Grade 3 CRS in 4 of 88 patients. No case reached grade 4 or above.
Neurotoxicity (ICANS)
No immune effector cell-associated neurotoxicity syndrome was reported in the study.
Stopped for side effects
No patient discontinued satri-cel because of a treatment-related adverse event.
Had a grade 3 or worse event
Nearly every patient experienced a severe treatment-emergent adverse event of some kind. This is intensive treatment delivered on a specialist ward, not an infusion clinic.
Where these figures come from
CT041-ST-01, a multicentre, open-label, randomised confirmatory study run in China: 156 patients randomised two-to-one to satri-cel or the investigator’s choice of treatment, led by Professor Shen Lin at Peking University Cancer Hospital, published in The Lancet in 2025 and presented at ASCO the same year. Data cut 18 October 2024. The results have been written into the 2026 CSCO gastric cancer guidelines.
Two things to hold onto. Every patient in the study was Chinese, so there is no published evidence yet in other populations. And the survival comparison is model-adjusted, because 42% of the control group later crossed over and received satri-cel themselves — which changes what the control arm can tell you.
Numbers, With Their Conditions Attached
A response rate quoted without its indication, its patient population and its follow-up period is close to meaningless. These are the published figures behind China’s approved products, each with the conditions that produced it.
Five-year overall survival
Real-world follow-up of China’s first approved CAR-T product (axicabtagene ciloleucel) in relapsed or refractory large B-cell lymphoma — long-term data, not an early read.
Objective response rate
A CD19-targeted product in relapsed or refractory haematological malignancy, reported in registrational studies — rapid reduction of tumour burden and deep remission.
Best complete response rate
Best CR/CRi across key clinical studies of a further CD19 product, meaning most patients reached a remission deep enough to be worth building on.
Two-year overall survival
Relapsed or refractory follicular lymphoma: no deaths among study patients at two years, with 80.3% showing no disease progression over the same period.
Figures as published in the clinical profile supplied to MedVoyage Global by StarWay Bio. They come from different products in different diseases and different patient groups, so they cannot be compared with one another and none of them is a forecast for an individual case. Which product applies to you — if any does — is determined by the treating centre after review.
Chongqing Precision Biotech
One of the manufacturers inside StarWay Bio’s network, and a useful illustration of what sits behind an approved product. Founded in 2016 and funded by a vaccine group listed on the Shenzhen exchange since 2010, it develops CD19 cell therapy with a focus most companies avoid: children and young adults.
Established in Chongqing, backed by a Shenzhen-listed vaccine group
Integrated R&D and production platform, plasmid to finished cells
Technical experts and research personnel on the development team
Peer-reviewed papers published by the team
Core technology inventions granted, from 170+ patents filed
International patents in the US, Japan, Germany, the EU and Singapore
Puzol-cel — a CD19 Therapy Built for Children
Eighty-nine patients, median age twelve. This was not a favourable cohort: 87.6% had already relapsed, 39.3% more than once, two-thirds carried high-risk genetic alterations, and the median bone marrow disease burden on entry was 61%. These are the results in that group.
Phase II results published at the American Society of Hematology annual meeting, 2024 (doi: 10.1182/blood-2024-206408). Response was assessed by an independent review committee. Subgroup analysis reported that high response rates held up in patients aged twelve and over, in refractory disease, after previous stem cell transplant, and in those carrying TP53 mutations or a high disease burden.
What the Side Effects Actually Are
CAR-T works by provoking a very large immune response, and that response is itself the main danger. Two reactions dominate. Both are common. Both are usually manageable in a centre equipped for them, and that is precisely why the therapy is restricted to designated hospitals.
The figures opposite come from the published paediatric study described above — eighty-nine heavily pre-treated patients. Rates differ by product, by disease and by how unwell a patient is at the point of infusion, so read them as an indication of what this treatment involves rather than as your own odds.
Cytokine Release Syndrome
A fierce inflammatory reaction as the engineered cells activate — fever, low blood pressure, difficulty breathing. It signals the treatment is working, and it still has to be managed carefully.
- Any grade97.8%
- Grade 3–427.0%
- Fatal (grade 5)None
- Median onsetDay 5
Neurological Toxicity
Confusion, difficulty finding words, tremor or reduced alertness in the days after infusion. Frightening to witness, generally reversible, and monitored for daily while you are in the unit.
- Any grade50.6%
- Grade 3–439.3%
- Fatal (grade 5)None
- Median duration5 days
Six Things That Actually Get Handled
A CAR-T case is not a flight and an appointment. It is an eligibility review, a manufacturing slot, a licensed centre, a long stay and a monitoring plan that follows you home — and every one of those can fail on paperwork rather than on medicine.
Eligibility Review First
Before anything else, your records go to a specialist to answer one question honestly: is CAR-T appropriate for this disease, at this stage, in this patient. A great many enquiries end here, and that is the correct outcome when it is.
Records, Imaging & Translation
Pathology, flow cytometry, cytogenetics, marrow reports, treatment history and imaging collected, translated properly and put in front of the right haematologist. Medical translation is a specialist job — a mistranslated pathology report is worse than none.
Centre & Product Matching
Each approved product is licensed to specific designated hospitals. Matching means finding the centre authorised for the product your disease actually calls for — and confirming they can take the case within a timeframe that makes sense.
Travel, Visa Papers & the Stay
CAR-T is not a week away from home. Collection, manufacturing, infusion and monitoring are separate stages spread over weeks. Travel documentation, accommodation for the whole window and arrangements for whoever comes with you are organised around the centre’s schedule.
Interpreting on the Ward
Professional interpreters for consultations, consent discussions and ward rounds. Consent to a treatment like this one is not something to sign through a translation app.
Follow-Up After You Fly Home
Discharge summaries, response assessments and monitoring schedules obtained and forwarded to your own haematologist, with remote contact to the treating team arranged for as long as the case needs it.
Four Steps, One Coordinator
Every case runs through MedVoyage Global. You speak to your coordinator; we speak to StarWay Bio and the treatment centre. Nothing about your treatment is decided in a conversation you are not part of.
Send the Diagnosis
Open your case with MedVoyage Global and send what you have — the pathology report, the marrow results, the treatment history, the imaging. For CAR-T, the details of what has already been tried matter as much as the diagnosis itself.
A Specialist Reads It
Your coordinator puts the case to StarWay Bio for review against the eligibility criteria of the approved products. You are told which target fits, whether you meet the criteria, and where the honest uncertainties sit.
You See the Plan Before You Commit
Which designated centre, which product, what the stages are, roughly how long you would be in China and what it is likely to cost — set out before you book anything. If CAR-T is not right for your case, we say so.
Treatment, Then Home
Documents, appointments, interpreters, accommodation and transfers coordinated around the treatment schedule — and follow-up carried on with your own doctors once you are back.
What This Partnership Is, and Is Not
Advanced cancer attracts more overselling than any other field in medicine. Here is where the boundaries sit, before you spend any time on this.
Approved in China, Not Everywhere
NMPA approval is a Chinese regulatory approval. Most of these products are not licensed by the FDA or the EMA, and treatment takes place in China under Chinese regulation. That is a real difference, and you should weigh it rather than skip past it.
This Is a Serious Treatment
Cytokine release syndrome and neurological toxicity are common after CAR-T and can be severe. They are manageable — which is exactly why the therapy is restricted to designated centres staffed and equipped to manage them — but nobody should walk into this treating it as routine.
Eligibility Is a Clinical Decision
Whether CAR-T is appropriate is decided by the treating haematologist or oncologist against published criteria — never by a coordinator, and never by us. Disease type, prior therapy, organ function and fitness all determine the answer.
A Range Is Not a Quote
The cost band on this page is indicative and covers the therapy itself. Hospital admission, lymphodepletion, bridging treatment, management of complications, length of stay and travel all sit on top, and all depend on your case. A real figure needs your records first.
Every Enquiry Comes Through Us
Your case is opened, managed and followed up by your MedVoyage Global coordinator. One point of contact from the first message to the last follow-up, whichever centre in the network ends up treating you.
StarWay Bio Is Not a Medical Provider
They are a cell and gene therapy commercial organisation, not a hospital. Every clinical decision belongs to the treating doctors at the designated centre. Records move under strict confidentiality throughout.
Before You Send Anything
The things patients and families ask most often about CAR-T in China. If yours is not here, ask it directly — with a treatment this specific, most of the useful answers depend on the individual case.
Your own immune cells are collected, genetically modified in a laboratory so they can recognise a specific protein on your cancer cells, grown into far larger numbers, and infused back into you. Nothing comes from a donor. The treatment is manufactured individually for one patient — which is both why it is powerful and why it is expensive.
In China today: relapsed or refractory large B-cell lymphoma, follicular lymphoma, B-cell acute lymphoblastic leukaemia in both adults and children, multiple myeloma, and — since June 2026 — advanced gastric and gastro-oesophageal junction cancer. Each has its own eligibility criteria, generally requiring that a defined number of previous treatments have already been tried, and in the case of gastric cancer that the tumour has been tested and found to carry the target protein.
Possibly, and it is worth finding out. Satri-cel is approved in China for advanced gastric or gastro-oesophageal junction adenocarcinoma that is Claudin18.2-positive and HER2-negative, in patients who have already failed at least two lines of treatment. In the study behind that approval, 41% of patients responded against 4% on standard treatment, and median survival among those who received it was 9.2 months against 4.0 months among those who did not. Those are real numbers from patients in a very similar position — but they are group averages from a Chinese study population, not a prediction for you. The tissue test and a specialist review of your records come first.
It is an immunohistochemistry stain done on tumour tissue that has usually already been taken — the biopsy or surgical specimen your own hospital holds. In many cases the block can be sent for testing without any new procedure. Satri-cel requires 2+ or 3+ staining in at least 40% of tumour cells; at that threshold roughly 57.6% of gastric cancers test positive, so it is far from a long shot. Around 60% of gastric cancer patients express the protein at some level. Send us the pathology report and we will tell you whether the test has already been done or whether the tissue needs to be sent.
That cannot be answered from a description of your diagnosis alone. It depends on the disease subtype, how many lines of treatment you have had, whether the target protein is present, your organ function and your general fitness. Send the records and a specialist will review them against the criteria. If the answer is no, you will be told that rather than invited to travel and find out.
Weeks rather than days. Cell collection, manufacturing, lymphodepletion, infusion and the monitoring period afterwards are separate stages, and manufacturing alone takes time that cannot be compressed. The treating centre sets the exact schedule once you are assessed, and we plan the stay around it — including for whoever travels with you.
The products described here are approved by China’s National Medical Products Administration and delivered commercially at designated hospitals — not trial therapy. But NMPA approval is a Chinese approval. Most of these products do not hold FDA or EMA licences, and separately there are several hundred CAR-T trials running in China which are genuinely investigational. It is worth being clear which of the two you are being offered, and we will tell you.
Commercial CAR-T in China typically falls in a band of roughly US$100,000 to US$150,000 for the therapy itself, against something in the order of US$500,000 to US$700,000 in the United States. Treat that as a range, not a quote: it excludes hospital admission, bridging therapy, management of complications, length of stay and travel, all of which depend entirely on your case.
The two that matter most are cytokine release syndrome — an intense immune reaction as the engineered cells activate — and neurological toxicity, which can affect speech, alertness and coordination. Both are common. In published Chinese studies of a paediatric product, cytokine release syndrome occurred in almost all patients and was severe in around a quarter, with no treatment-related deaths reported in that cohort. Severity varies a great deal by product and by disease: in the gastric cancer study of satri-cel, severe cytokine release syndrome occurred in 4.5% of patients, none reached grade 4, and no neurotoxicity was reported at all — although almost every patient still had a severe adverse event of some kind. This is why treatment happens only at centres set up to manage it, and why the monitoring period afterwards is not optional.
Yes, and it is better when they do. Records go both ways: their notes inform the eligibility review, and the discharge summary, response assessments and follow-up schedule come back to them. Long-term monitoring after CAR-T usually happens at home, so your own team needs to know exactly what was given.
Each approved product is licensed to a specific list of designated treatment centres — a hospital cannot deliver a CAR-T product it is not authorised for. Once the product that fits your disease is identified, the centre follows from that. You are told which one and why before anything is committed.
Find Out Whether You Are Eligible
Send the diagnosis, the pathology and the record of what has already been tried. A specialist will read it against the criteria of the approved therapies and tell you straight whether CAR-T in China is a real option for your case — including when the answer is no.
All enquiries about StarWay Bio and its treatment network are handled by MedVoyage Global. StarWay Bio is a cell and gene therapy commercial organisation, not a medical institution, and does not provide medical services. Nothing on this page is medical advice or a promise of treatment, eligibility or outcome.